Summary
Bacteriophage T4 provides a simple model system in which to examine the mechanism of action of antitumor agents that have been proposed to attack type II DNA topoisomerases. Prior results demonstrated that T4 type II DNA topoisomerase is the target of antitumor agent 4′-(9-acridinylamino)methanesulfon-m-anisidide (m-AMSA) in phage-infected Escherichia coli: a point mutation in topoisomerase structural gene 39 was shown to confer both m-AMSA-resistant phage growth and m-AMSA-insensitive topoisomerase activity. We report here that a point mutation in T4 topoisomerase structural gene 52 can also independently render both phage growth and topoisomerase activity resistant to m-AMSA. The DNA relaxation and DNA cleavage activities of this newly isolated mutant topoisomerase were significantly insensitive to m-AMSA. The drug-resistance mutation in gene 52, as well as that in gene 39, alters the DNA cleavage site specificity of wild-type T4 topoisomerase. This fording is consistent with a mechanism of drug action in which both topoisomerase and DNA participate in formation of the drug-binding site.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Bernstein H, Bernstein C (1989) Bacteriophage T4 genetic homologies with bacteria and eucaryotes. J Bacteriol 171:2265–2270
Bradford MM (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72:248–254
Chow K-C, MacDonald TL, Ross WE (1988) DNA binding by epipodophyllotoxins and N-acyl anthracyclines: Implications for mechanism of topoisomerase II inhibition. Mol Pharmacol 34:467–473
Cozzarelli NR (1980) DNA gyrase and the supercoiling of DNA. Science 207:953–960
Dabrowiak JC (1983) Sequence specificity of drug-DNA interactions. Life Sci 32:2915–2931
Davis EM (1988) Protein assays: A review of common techniques. Am Biotech Lab 6(7):28–37
Drlica K, Franco RJ (1988) Inhibitors of DNA topoisomerases. Biochemistry 27:2253–2259
Fox KR, Waring MJ, Brown JR, Neidle S (1986) DNA sequence preferences for the anti-cancer drug mitoxantrone and related anthraquinones revealed by DNase I footprinting. FEBS Lett 202:289–294
Gellert M, Mizuuchi K, O'Dea ME, Itch T, Tomizawa J (1977) Nalidixic acid resistance: A second genetic character involved in DNA gyrase activity. Proc Natl Acad Sci USA 74:4772–4776
Gellert M, Fisher LM, Ohmori H, O'Dea MH, Mizuuchi K (1981) DNA gyrase: Site-specific interactions and transient doublestrand breakage of DNA. Cold Spring Harbor Symp Quant Biol 45:391–398
Glisson BS, Ross WE (1987) DNA topoisomerase II: A primer on the enzyme and its unique role as a multidrug target in cancer chemotherapy. Pharmacol Ther 32:89–106 Huang WM (1986a) Nucleotide sequence of a type II DNA topoisomerase gene. Bacteriophage T4 gene 39. Nucleic Acids Res 14:7751–7765
Huang WM (1986b) The 52-protein subunit of T4 DNA topoisomerase is homologous to the gyrA-protein of gyrase. Nucleic Acids Res 14:7379–7390
Huff AC, Kreuzer KN (1990) The mechanism of antitumor drug action in a simple bacteriophage model system. In: Potmesil M, Ross WE (eds) DNA topoisomerases and cancer. Oxford University Press, New York, in press
Huff AC, Leatherwood JK, Kreuzer KN (1989) Bacteriophage T4 DNA topoisomerase is the target of antitumor agent 4′-(9-acridinylamino)methanesulfon-m-anisidide (m-AMSA) in T4-infected Escherichia coli. Proc Natl Acad Sci USA 86:1307–1311
Kreuzer KN, Alberts BM (1984) Site-specific recognition of bacteriophage T4 DNA by T4 type II DNA topoisomerase and Escherichia coli DNA gyrase. J Biol Chem 259:5339–5346
Kreuzer KN, Huang WM (1983) T4 DNA topoisomerase. In: Mathews CK, Kutter EM, Mosig G, Berget PB (eds) Bacteriophage T4. American Society for Microbiology, Washington DC, pp 90–96
Kreuzer KN, Jongeneel CV (1983) Escherichia coli phage T4 topoisomerase. Methods Enzymol 100:144–160
Kutter E, Ruger W (1983) Map of the T4 genome and its transcription control sites. In: Mathews CK, Kutter EM, Mosig G, Berget PB (eds) Bacteriophage T4. American Society for Microbiology, Washington DC, pp 277–290
Liu LF (1983) DNA topoisomerases — enzymes that catalyse the breaking and rejoining of DNA. CRC Crit Rev Biochem 15:1–24
Lutz CT, Hollifield WC, Seed B, Davie JM, Huang HV (1987) Syrinx 2A: An improved λ phage vector designed for screening DNA libraries by recombination in vivo. Proc Natl Acad Sci USA 84:4379–4383
Maxwell A, Gellert M (1986) Mechanistic aspects of DNA topoisomerases. Adv Protein Chem 38:69–107
Nelson EM, Tewey KM, Liu LF (1984) Mechanism of antitumor drug action: Poisoning of mammalian DNA topoisomerase II on DNA by 4′-(9-acridinylamino)-methanesulfon-m-anisidide. Proc Nail Acad Sci USA 81:1361–1365
Robbie M, Wilkins RJ (1984) Identification of the specific sites of interaction between intercalating drugs and DNA. Chem-Biol Interact 49:189–207
Rowe TC, Tewey KM, Liu LF (1984) Identification of the breakage-reunion subunit of T4 DNA topoisomerase. J Biol Chem 259:9177–9181
Seasholtz AF, Greenberg GR (1983) Identification of bacteriophage T4 gene 60 product and a role for this protein in DNA topoisomerase. J Biol Chem 258:1221–1226
Shen LL, Kohlbrenner WE, Weigl D, Baranowski J (1989a) Mechanism of quinolone inhibition of DNA gyrase. Appearance of unique norfloxacin binding sites in enzyme-DNA complexes. J Biol Chem 264:2973–2978
Shen LL, Mitscher LA, Sharma PN, O'Donnell TJ, Chu DWT, Cooper CS, Rosen T, Pernet AG (1989b) Mechanism of inhibition of DNA gyrase by quinolone antibacterials: A cooperative drug-DNA binding model. Biochemistry 28:3886–3894
Shure M, Pulleyblank DE, Vinograd J (1977) The problems of eukaryotic and prokaryotic DNA packaging and in vivo conformation posed by superhelix density heterogeneity. Nucleic Acids Res 4:1183–1205
Sugino A, Peebles CL, Kreuzer KN, Cozzarelli NR (1977) Mechanism of action of nalidixic acid: Purification of Escherichia coli nalA gene product and its relationship to DNA gyrase and a novel nicking-closing enzyme. Proc Natl Acad Sci USA 74:4767–4771
Sullivan DM, Latham MD, Rowe TC, Ross WE (1989) Purification and characterization of an altered topoisomerase II from a drug-resistant Chinese hamster ovary cell line. Biochemistry 28:5680–5687
Tewey KM, Chen GL, Nelson EM, Liu LF (1984a) Intercalative antitumor drugs interfere with the breakage-reunion reaction of mammalian topoisomerase II. J Biol Chem 259:9182–9187
Tewey KM, Rowe TC, Yang L, Halligan BD, Liu LF (1984b) Adriamycin-induced DNA damage mediated by mammalian DNA topoisomerase II. Science 226:466–468
Tse Y-C, Kirkegaard K, Wang JC (1980) Covalent bonds between protein and DNA. Formation of phosphotyrosine linkage between certain DNA topoisomerases and DNA. J Biol Chem 255:5560–5565
Wang JC (1985) DNA topoisomerases. Annu Rev Biochem 54:665–697
Waring M (1970) Variation of the supercoils in closed circular DNA by binding of antibiotics and drugs: Evidence for molecular models involving intercalation. J Mol Biol 54:247–279
Waring MJ (1981) DNA modification and cancer. Annu Rev Biochem 50:159–192
Yamagishi J, Yoshida H, Yamayoshi M, Nakamura S (1986) Nalidixic acid-resistant mutations of the gyrB gene of Escherichia coli. Mol Gen Genet 204:367–373
Yanisch-Perron C, Vieira J, Messing J (1985) Improved M13 phage cloning vectors and host strains: Nucleotide sequences of the M13mp18 and pUC19 vectors. Gene 33:103–119
Yoshida H, Kojima T, Yamagishi J, Nakamura S (1988) Quinolone-resistant mutations of the gyrA gene of Escherichia coli. Mol Gen Genet 211:1–7
Author information
Authors and Affiliations
Additional information
Communicated by N.D.F. Grindley
Rights and permissions
About this article
Cite this article
Huff, A.C., Ward, R.E. & Kreuzer, K.N. Mutational alteration of the breakage/resealing subunit of bacteriophage T4 DNA topoisomerase confers resistance to antitumor agent m-AMSA. Molec. Gen. Genet. 221, 27–32 (1990). https://doi.org/10.1007/BF00280363
Received:
Issue Date:
DOI: https://doi.org/10.1007/BF00280363